Lichen sclerosus
Chernova 2016Experience in management of patients with lichen sclerosus and HPV infection of the vulva
There is growing interest in the use of several innovative technologies being routinely used for facial skin care and skin rejuvenation for the treatment of genital disorders resulting from the aging process or with inflammation-related origins. This includes the use of PRP.
Lichen sclerosus (LS) is a chronic inflammatory dermatitis that creates patchy, white skin that appears thinner than normal. It usually affects the genital and anal areas. Most symptomatic patients complain of pruritus and burning or soreness, dysuria or dyspareunia.
OBJECTIVE
Evaluate the use of RegenPRP™ combined with antiviral and laser therapies for the symptomatic treatment of lichen sclerosus in patients with a concomitant papillomavirus infection.
PROTOCOL
Prospective study on 40 women with lichen sclerosus and papillomavirus infection of the vulva. Patients were injected with 4-8 ml of RegenPRP™ in the affected area using mesotherapy technique. The next day, antiviral Panavir gel was applied to the lesion followed by low-level laser light treatment (LLLT). Patients received 3 courses at 4-week intervals. Severity of nine symptoms were evaluated, among them itching, hypopigmentation, and oedema.
RESULTS
Before treatment, all 40 patients presented with extremely severe symptoms of itching and hypopigmentation; in addition, 32/40 patients presented with extremely severe symptoms of oedema (See Table 1). One month after treatment, 12/40 patients reported only mild itching, the remaining 28 patients were without itching symptoms. The number of patients reporting severe hypopigmentation was reduced from 40 to 8, with 32 patients reporting no (16) or mild hypopigmentation (16). Twenty-eight patients reported no more oedema symptoms (See Table 1).
Significant decrease in clinical symptoms
The study reports effectiveness in 36 of 40 patients following the combined treatment. This outcome cannot be attributed to RegenPRP™ alone.
Itching
No itching after treatment
28 / 40 patients · at 1 month
Oedema
No oedema after treatment
28 / 40 patients · at 1 month
Hypopigmentation
No or mild hypopigmentation
32 / 40 patients · at 1 month
How symptom severity changed
Before treatment vs 1 month after treatment · each bar represents all 40 patients.
Itching
Hypopigmentation
Oedema
CONCLUSION
RegenPRP™ combined with antiviral and LLLT therapy was effective in 90% of cases (36/40) as indicated by a significant decrease in all clinical symptoms that were evaluated.
View patient counts and study details
Prospective study of 40 women. RegenPRP™ injections (4–8 ml) were combined with Panavir antiviral gel and LLLT. Three treatment courses were administered at 4-week intervals. Nine symptoms were evaluated; the brochure tabulates the three shown here. No comparator group is described on the supplied page.
| Symptom | Time | No symptom | Mild | Severe | Extremely severe |
|---|---|---|---|---|---|
| Itching | Before | 0 | 0 | 0 | 40 |
| Itching | After | 28 | 12 | 0 | 0 |
| Hypopigmentation | Before | 0 | 0 | 0 | 40 |
| Hypopigmentation | After | 16 | 16 | 4 | 4 |
| Oedema | Before | 0 | 0 | 8 | 32 |
| Oedema | After | 28 | 8 | 4 | 0 |